Welcome to our dedicated page for Ehave news (Ticker: EHVVF), a resource for investors and traders seeking the latest updates and insights on Ehave stock.
The Ehave Inc. (EHVVF) news feed on Stock Titan aggregates company communications and related updates that describe its evolution into an applied artificial intelligence platform operator. Recent press releases highlight Ehave’s acquisition of AIHeadHunter, an AI-powered recruitment platform designed to automate and streamline executive search and talent sourcing through advanced data analysis. These announcements provide insight into how Ehave is repositioning itself around data-driven technology assets and AI-enabled business models.
News linked to Ehave also frequently references its subsidiary AIBotics, Inc. (traded as AIBT), which is described as a developer and manager of AI- and robotics-enhanced technologies. AIBotics press releases cover topics such as the development and pilot deployment of the Phill Robot™ massage robot, the Milkyway smart refrigerator, and partnerships aimed at distributing service robots in markets like Israel and Jamaica. These items illustrate how Ehave’s subsidiary is working with AI, robotics, and agentic AI concepts to build products and platforms for wellness, service environments, and intelligent automation.
Investors and observers using this news page can review how Ehave describes its strategic realignment, including its focus on incubating scalable AI platforms and structuring transactions to support that shift. Coverage includes acquisition terms for AIHeadHunter, descriptions of the technology licensed for that platform, and statements about Ehave’s plans to fund and launch enterprise pilots. For AIBotics, the news flow includes product development milestones, collaboration agreements for UI/UX and operating platforms, and early commercialization efforts such as pilot programs in fitness and wellness facilities.
By following the EHVVF news page, readers can see how Ehave communicates its progress on AIHeadHunter, its relationship with AIBotics, and its broader approach to applied AI and robotics. The articles provide context on the company’s stated objectives, the markets it is targeting through its platforms, and the partnerships it reports as part of its growth plans.
Ehave, Inc. (EHVVF), a provider of digital therapeutics in the psychedelic and mental health sectors, announced that its CEO, Benjamin Kaplan, will appear on the Psychedelic Spotlight segment of New to the Street. The segment will air on NewsMax on March 14th at 10:00 AM EST and on Fox Business on March 15th at 7:30 PM EST. This appearance is an opportunity for shareholders to gain insight into Ehave and the psychedelic sector. Ehave focuses on improving care for brain disorders through innovations like the Ehave Telemetry Portal.
Ehave, Inc. (OTC Pink: EHVVF) has filed a trademark application for its KetaDASH brand with the USPTO, accepted on February 26, 2021. This move aims to protect its brand as the company prepares for beta trials of its ketamine IV therapy in Q2 2021, utilizing advanced vein technology. Ehave has also filed to uplist to the OTCQB. KetaDASH provides a platform for patients to receive supervised ketamine treatment at home, connecting them with skilled nurses.
Ehave, Inc. (EHVVF) has announced plans to launch a beta trial of its innovative KetaDASH ketamine IV therapy in Q2 2021. This platform connects patients with skilled nurses to provide ketamine therapy at home, enhancing patient accessibility and comfort. Ehave has secured liability insurance for its services, eliminating additional costs for clinics. The partnership with Vein-Eye Carry aims to improve IV access success rates, which can fail in up to 40% of critically ill patients. CEO Ben Kaplan emphasizes the urgent need for effective mental health treatments, positioning KetaDASH as a significant advancement.
Ehave, Inc. (EHVVF) announced the upcoming launch of its at-home ketamine delivery platform, KetaDASH, aimed at treating depression rapidly. Ketamine has shown effectiveness for various mental health disorders, with effects often felt within 40 minutes. Ehave leverages its digital therapeutic technology to empower medical practitioners in administering treatments effectively.
The total addressable market for ketamine in depression treatment is estimated at $16.2 billion. Despite recent advancements, KetaDASH is not yet FDA-approved for depression treatments, which presents a potential challenge.